Claudia Kunz

A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

Wolfgang Wick, Harald Fricke, Klaus Junge et al. · Clinical Cancer Research · 2014 · 126 citations

Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients

Jochen Tuettenberg, Marcel Seiz, Klaus‐Michael Debatin et al. · International Immunopharmacology · 2012 · 37 citations · Full text

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

Jonas Blaes, Carina M. Thomé, Philipp-Niclas Pfenning et al. · Molecular Cancer Research · 2018 · 34 citations · Full text

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients

Nina Hanke, Claudia Kunz, Meinolf Thiemann et al. · Pharmaceutics · 2019 · 19 citations · Full text

Pharmacotherapy, High-grade Gliomas, Glioma +26

Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS

Tobias Boch, Thomas Luft, Georgia Metzgeroth et al. · Leukemia Research · 2018 · 15 citations

Intermediate Risk Mds, Transfusion Medicine, Transfusion-dependent Patients +6